News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IPO Watch: CombinatoRx, Incorporated And The Biological Two-Step



10/19/2005 5:12:59 PM

CombinatoRx finds itself in that familiar rock/hard-place difficulty. The rock is a lousy IPO market, which is very grudging in its valuations of development-stage biotechs, and the hard place is not having any money. The premise behind CombinatoRx is that biological pathways are often double. Thus, a drug may be efficacious against one pathway, only to have a disease make an end-run down a secondary route. To outsmart the disease, CombinatoRx screens a library of 2,000 already-approved drugs to see if a combination of any two could plausibly treat an illness even if neither one of them is currently used against the disease or if adding a second drug could increase the first drug’s effectiveness. We look at the pipeline of the company and its finances. In the last two months, most biotechs have chosen to postpone their offerings rather than reduce the IPO price down to fire-sale levels. Will CombinatoRX face the same unpleasant, lesser-of-two-evils choice?



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES